Genentech; Prometheus Laboratories Inc. . Finance Report 2021. Short version. FDA Grants Priority Review to Genentech's Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma. Multifocal Motor Neuropathy Market to Surge Past a Revenue CAGR of 3.6% 2021 Group guidance unchanged Basel, July 21, 2021 - commenting on the quarter, Vas Narasimhan, CEO of Novartis, said: "Novartis delivered a strong second quarter, driven by the momentum of our key growth brands , including . Adaptive Biotech downgraded by Goldman Sachs on Genentech exit The Global Asthma Medication market is anticipated to rise at a considerable rate during the forecast period, between 2022 and 2030. Avanade has 56,000 employees, and the revenue per employee ratio is $35,714. Multifocal Motor Neuropathy Market to Surge Past a Revenue The company manufactures drugs using technology to bring treatments for rare diseases to patients. Full year 2021 GAAP and Non-GAAP R&D expense includes a total of $285 million in payments related to our collaborations with InnoCare Pharma Limited, Ionis, Bio- Thera Solutions, Ltd., Genentech, Capsigen Inc., and Ginkgo Bioworks. Roche - Statistics & Facts | Statista Bayer revenue from 2010 to 2022. Genentech peak revenue was $166.9M in 2022. Genentech makes $457,260 in a day. Genentech revenue is $166.9M annually. A deal being announced today with Genentech points the way for 23andMe, the personal genetics company backed by Facebook billionaire Yuri Milner and Google Ventures to become a sustainable business even if the companys discussions with the U.S. Food and Drug Administration stretch on for [], When the US biotech company Regeneron Pharmaceuticals recently announced its first-quarter results, few were surprised that the company's flagship wet age-related macular degeneration (AMD) product Eylea had once again exceeded consensus expectations. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Genentech: Press Releases | Sunday, Jul 18, 2021 Net income for the year was $20.8 million, down 53% on the 1991 levels. Solutions. After extensive research and analysis, Zippia's data science team found the following key financial metrics. Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year Avanade peak revenue was $2.0B in 2022. Roche | Investor downloads Our patient resource center is dedicated to getting patients and caregivers to the right resources. Intravenous infusion, tocilizumab, for hospitalized adults . AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results | AbbVie It was a good year to be a pharmaceutical company, especially one that came up with a product to combat COVID-19. The top 20 drugs by worldwide sales in 2020 | Fierce Pharma The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Roche Diagnostics Revenues Grow 29 Percent in 2021 The biotechnology company reported ($3.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.50) by $1.28. Herceptin is a drug used in the treatment of some types of breast cancer. Chairman and CEO Letter and Amgen Inc. 2019 Annual Report 12.6 MB. Ascendis | Financial results Top 15 Best-Selling Drugs Launched in 2020 - genengnews.com Do Not Sell or Share My Personal Information, Limit the Use of My Sensitive Personal Information. Leading biotech and pharma product launches in 2023 and revenue forecasts for 2028 (in billion U.S. dollars) Sales share at risk of pharmaceuticals due to patent expiries U.S. 2022 Sales share at. New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema, Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting, FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-Cell Lymphoma, Genentechs Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study, Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023, New Four-Year Data for Genentechs Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA), FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma, New Phase III Data Show Genentechs Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO), Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition, Genentechs Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial, FDA Grants Priority Review to Genentechs Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma, FDA Approves Genentechs Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma, FDA Approves Genentechs Actemra for the Treatment of COVID-19 in Hospitalized Adults, Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma, Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022, Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth, Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimers Disease, Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs, Early Treatment With Genentechs Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile, Positive Topline Phase III Results Show Genentechs Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO), Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022, Positive New Data for Genentechs Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA), FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma, Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older, Genentechs Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results, Genentech to Present Scientific Progress Across Alzheimers Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting, New Two-Year Data Confirm Genentechs Vabysmo Improves Vision With Fewer Treatments for People With Wet-Age-Related Macular Degeneration, New Data From Phase III Haven 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentechs Hemlibra (emicizumab-kxwh) in People with Moderate or Mild Hemophilia A, FDA Grants Priority Review to Genentechs Mosunetuzumab for People with Relapsed or Refractory Follicular Lymphoma, Genentech Provides Update on Alzheimers Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimers Disease, Genentech Announces Positive Data From Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting, FDA Approves Genentechs Evrysdi (risdiplam) For Use in Babies Under Two Months with Spinal Muscular Atrophy (SMA), New Pivotal Data Demonstrate Clinical Benefit of Genentechs Glofitamab, a Potential First-in-Class Bispecific Antibody for People with Aggressive Lymphoma, Data at the 2022 ASCO Annual Meeting Highlight Genentechs Continued Commitment to Innovation in Oncology and Personalized Healthcare, Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer, New Three-Year Data for Genentechs Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA), U.S. FDA Grants Priority Review to Genentechs Actemra for the Treatment of COVID-19 in Hospitalized Adults, New Data for Genentechs Ocrevus (Ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis, Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer, Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting, New Data for Genentechs Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA), New Two-Year Data for Genentechs Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss, FDA Approves Genentechs Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss, The Lancet Publishes Studies Showing Genentechs Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months, Genentechs Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA), Genentechs Polivy Combination Reduced the Risk of Disease Worsening or Death by 27% in People With Previously Untreated Aggressive Form of Lymphoma, Interim Data From Phase III HAVEN 6 Study Demonstrate Favorable Safety and Efficacy Profile of Genentechs Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A, Genentech Presents Pivotal Data at ASH 2021 for Novel Cancer Immunotherapy Mosunetuzumab, New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentechs Novel Anti-TIGIT Tiragolumab Plus Tecentriq, Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders, FDA Approves Genentechs Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD), FDA Approves Genentechs Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer, New 4-Year Data Show Genentechs Enspryng (satralizumab-mwge) Significantly Reduces Debilitating Relapses in People With Neuromyelitis Optica Spectrum Disorder, New Data up to 8-Years for Genentechs Ocrevus (ocrelizumab) Show Early and Ongoing Treatment Significantly Reduced Risk of Requiring a Walking Aid in Relapsing Multiple Sclerosis and Disability Progression in Primary Progressive Multiple Sclerosis, Genentechs Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy Designation in Alzheimers Disease, Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021, New Phase III Data Support the Benefit of Genentechs Tecentriq in Early-Stage Lung Cancer, Genentech to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significant Progress in Early Stage and Uncommon Cancers, Genentech Provides Update on Tecentriq U.S. The drug generated $7.12 billion in 2019, enough for the No. Read more news. Marc Tessier-Lavigne Three former top researchers at Genentech, the legendary biotech that is now part of Roche Holding, have raised $217 million in venture capital to start a new company, Denali Therapeutics, focused on treating and curing neurodegenerative diseases like Alzheimers, ALS, and Parkinsons. Genentech - a member of the Roche group - has announced that its phase 3 study of Tecentriq (atezolizumab) combination mets its primary . With three-monthly sales of $314 million, management reiterated that full-year revenues for 2013 are expected to hit $1.3 []. - Senior Reporter, San Francisco Business Times Aug 30, 2021 Updated Aug 30, 2021, 2:50pm PDT Amid a closer look by regulators at cancer drugs given accelerated approval, Genentech Inc.. . After extensive research and analysis, Zippia's data science team found the following key financial metrics. The drivers' decision mirrors that of Facebook shuttle drivers, who voted for union representation [], Drug companies usually avoid head-to-head clinical trials against tough competitors. Newark, New Castle, USA, April 28, 2023 (GLOBE NEWSWIRE) In accordance with the most recent analysis by Growth Plus Reports, the global market for multifocal motor neuropathy is expected to expand at a revenue CAGR of 3.6% in between 2023 to 2031. 21 Dec 2022. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. The employee data is based on information from people who have self-reported their past or current employments at Genentech. [4] Historically, the company is regarded as the world's first biotechnology company. Genentech has 13,638 employees, and the revenue per employee ratio is $12,237. Of the world's top 20 pharmas ranked by 2021 revenues, 12 had at least 10% . "We successfully completed the transformative Allergan acquisition and delivered another year of strong results in 2020, despite the challenges presented by the global pandemic," said Richard A. Gonzalez, chairman and chief executive . Use Forbes logos and quotes in your marketing. Click on the image to the left and discover the Chiesi Group Annual and Sustainability Report 2021. This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Full year GAAP SG&A expense was $2,674 million as compared to $2,505 million for the full year 2020. Safety for both Genentech Research and Early Development operates as an independent center within Roche. If the patient was enrolled in a Medicare Advantage plan in 2020 and 2021, submit the COVID-19 vaccine and mAb infusion claims to original Medicare. This site is intended for US residents only. The global multifocal motor neuropathy market revenue is driven by the key factors that . Full-Year 2021 Presentation with appendix. infectious disease Genentech: Press Releases Eight years later, Regeneron, Gilead, Genentech and hundreds of other companies use its collaborative R&D software. With no material changes to the operating or capital expenses, Adaptive also reaffirmed its 2021 revenue . Company Information - Genentech After extensive research and analysis, Zippia's data science team found the following key financial metrics. Roche reports solid results in 2020 - GlobeNewswire News Room Total revenues for full-year 1992 at Genentech in the USA grew 5.5% to $544.2 million. Genentech: Contact Details and Business Profile - RocketReach Back in 2008, Genentechs top drugs were Avastin, Rituxan, Herceptin, and Lucentis, which generated sales of over $7 billion. Cancer Immunotherapy Market Size Worth USD 388.25 Billion in 2030 BioSpace Looks at the Top 8 Biopharma Companies by Net Income PDF FINANCIAL RESULTS | RSULTATS FINANCIERS | FINANZERGEBNISSE - Novartis Excluding the unfavorable impact of foreign exchange of $11 million and the impact of divestitures and discontinuations of $2 million, the Bausch + Lomb segment increased organically 1,7 by . In the face of Roche's hostile bid, Genentech's executives are angling for a higher price. New Data for Genentech's Hemlibra (emicizumab-kxwh) Reinforce Safety Profile in People With Hemophilia A. JPMorgan Chase Agrees To Acquire First Republic Banks Deposits After FDIC Intervention, She Was Losing Her Vision Until Science Saved Her Sight, Memorial Sloan Kettering, Genentech, Jiahui Health To Join Forbes China Health Summit On Aug. 15, Memorial Sloan Kettering, Genentech, Jiahui Health To Join Forbes China Healthcare Summit On Aug. 15, How A Tool For Scientists Became A Billion-Dollar Opportunity. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. Roche To Top $66 Billion In Sales By 2020, Led By Neuroscience - Forbes Genentech General Information. Genentech, Inc. Corporate Giving Program | Foundation Directory | Candid Related by Industry: Drugs & Biotechnology, Located in San Francisco-Oakland-Fremont, CA Metropolitan Area. Genentech ended 2008 with a net income of more than $3.6 billion, versus $9.33 billion for Roche. JP Morgan Healthcare Conference 2021, Day 1: Roche, Seer, 10x, Guardant A look at our approvals past and present. Assay Development Scientist jobs at Genentech, Control Systems Engineer jobs at Genentech, Manufacturing Production Technician jobs at Genentech, Project Manager Integrated jobs at Genentech, Senior Automation Engineer jobs at Genentech, Talent Acquisition Partner jobs at Genentech, Director Of Programs And Operations jobs at Genentech. Genentech Revenue: Annual, Quarterly, and Historic - Zippia Pfizer expects to bring in $15 billion from the vaccine in 2021, which would greatly contribute to the $59 billion to $61 billion it expects to earn overall for the year. ophthalmology, oncology Biogen : Reports Q4 2021 Earnings | MarketScreener . Industry: Biotechnology & Pharmaceuticals: Industry Vertical: Biotechnology: Founded: 1,976: HQ Location: South San Francisco, Calif. Sites: 9: U.S. Employees: 13,588 In 2021, the market is growing at a steady rate and with the . Genentech revenue is $166.9M annually. [5] As of July 2021, Genentech employed 13,539 people. Its main products are an antibody for cancer and medicine for . Acquisitions Funding Investments News & Insights CEO Alexander Hardy CEO Approval Rating 76/100 Weigh In 1976 South San Francisco California San Francisco Bay Area The Logic Of Biologics - Is Regeneron The Next Genentech? Founded more than 30 years ago, Genentech (gene.com) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life threatening medical conditions. Was The $47 Billion Acquisition of Genentech In 2009 A Good Deal For Roche? 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 . Our pipeline includes new molecular entities that address serious unmet medical needs. Inclusion and diversity are integral to innovation and equitable care. Genentech - Overview, News & Competitors | ZoomInfo.com The company, a member of the Roche Gro Read More Contact Who is Genentech Headquarters Roche Holding (NASDAQ:RHHBY) acquired Genentech, a pharmaceuticals company with three blockbuster oncology drugs, in 2009 for a sum of $47 billion. The data presented on this page does not represent the view of Genentech and its employees or that of Zippia. immunology. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or patientinfo@gene.com. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. COVID-19 vaccine and monoclonal antibodies billing for Part A 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in 2020. immunology Community Guidelines: 1. From 2021 the Report is also online via chiesireport.com. 22 Dec 2022. . Full-Year 2022 Presentation without appendix, Full-Year 2022 Presentation with appendix, Nine-month 2022 Presentation without appendix, Nine-month 2022 Presentation with appendix, Half-Year 2022 Presentation without appendix, Half-Year 2022 Presentation with appendix, Full-Year 2021 Presentation without appendix, Full-Year 2021 Presentation with appendix, Nine-month 2021 Presentation without appendix, Nine-month 2021 Presentation with appendix, Half-Year 2021 Presentation without appendix, Half-Year 2021 Presentation with appendix, Full-Year 2020 Presentation with appendix, Full-Year 2020 Presentation without appendix, Rejuvenation and Transformation - Jefferies Virtual London Healthcare Conference, Rejuvenation and Transformation - UBS European Virtual Conference, Nine-month 2020 Presentation without appendix, Nine-month 2020 Presentation with appendix, Roche Pharma Day 2020 - Infectious diseases, Roche Pharma Day 2020 - Commercial Opportunities, Roche Pharma Day 2020 - Patient populations, Roche Pharma Day 2020 - Pipeline overview, Roche Pharma Day 2020 - Immunology & Ophthalmology, Half-Year 2020 Presentation without appendix, Half-Year 2020 Presentation with appendix, Exane BNPP European CEO Conference, June 2020, Bryan Garnier Oncology Day - Conference Call, June 2020, Strategy, Rejuvenation, and Transformation, Digital technology and advanced analytics, Genentech Research and Early Development (gRED), SMA Europe 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy, Paris-Evry, 2020, Full-Year 2019 Presentation with appendix, The Octavian Seminar, Zurich, January 2020, JPMorgan Healthcare Conference, San Francisco, 2020, Jefferies 2019 London Healthcare Conference, UBS European Conference London, 13th November 2019, Roche analyst audio webcast, 12 November 2019, Early Drug Development Investor Relations Event 2019, Nine-month 2019 sales Presentation without appendix, Nine-month 2019 sales Presentation with appendix, European Society for Medical Oncology (ESMO) 2019 Congress Highlights from Roche, Roche Pharma Day 2019 - Pipeline overview, Roche Pharma Day 2019 - Immunology & Infectious diseases, Roche Pharma Day 2019 - Commercial Opportunities, Roche Pharma Day 2019 - Patient populations, Half-Year 2019 Presentation without appendix, Half-Year 2019 Presentation with appendix, UBS Global Healthcare Conference NY, 2019, American Academy of Neurology (AAN) 2019 Congress, 39th Cowen and Company Annual Health Care Conference, Full-Year 2018 Presentation with appendix, J.P. Morgan 37th Annual Healthcare Conference, 2018 American Society of Hematology's 60th Annual Meeting, European Society for Medical Oncology (ESMO) 2018 Congress, Nine-month 2018 sales Presentation without appendix, Nine-month 2018 sales Presentation with appendix, Bernstein's 15th Annual Pan European Strategic Decisions Conference (SDC), IASLC World Conference on Lung Cancer 2018, Half-Year 2018 Presentation without appendix, Half-Year 2018 Presentation with appendix, Bernsteins 34th Annual Strategic Decisions CEO Conference (SDC), Roches Virtual Pipeline Event from WFH 2018 World Congress, World Federation of Hemophilia (WFH) 2018 World Congress, Bank of America Merrill Lynch 2018 Healthcare Conference, Full-Year 2017 Presentation with appendix, J.P. Morgan 36th Annual Healthcare Conference, Nine-month sales 2017 Presentation with appendix, Bernstein 2017 European Strategic Decisions Conference, Roche Analyst Event on Diagnostics Division at AACC 2017, Half-Year 2017 Presentation with appendix, Exane BNP Paribas 19th European CEO Conference 2017, Jefferies 2017 Global Healthcare Conference, Bernstein 33rd Annual Strategic Decisions Conference, UBS Global Life Sciences Conferences 2017, Barclays Global Healthcare Conference 2017, Cowen and Company 37th Annual Healthcare Conference 2017, Full Year 2016 Presentation with appendix, Full Year 2016 Presentation without appendix, Nine-month sales 2016 Presentation with appendix, Bernstein Strategic Decisions Conference 2016, Roche Analyst Event on Diagnostics Division at AACC 2016, Jefferies 2016 Global Healthcare Conference, Vontobel Summer Conference - Committed to innovation and growth, dbAccess German, Swiss & Austrian Conference 2016, UBS Global Healthcare Conference - May 2016, Cowen and Company 36th Annual Health Care Conference, Pharma Day 2015 - afternoon sessions breakouts, Pharma Day 2015 - morning and afternoon sessions, UBS European Conference in London - 10th of November 2015, Nine-month sales 2015 Presentation with appendix, Sanford C. Bernstein Strategic Decisions Conference, Jefferies 2015 Global Healthcare Conference, Roche Half-Year Results 2015 webcast and conference call, Roche Analyst Event on Diagnostics Division at AACC 2015, dbAccess German, Swiss & Austrian Conference 2015, Bank of America Merrill Lynch 2015 Healthcare Conference, Bernstein's 31 Annual Strategic Decisions Conference, Roche investor conference call on the strategic collaboration with Foundation Medicine, Oppenheimer 25th Annual Healthcare Conference, Genentech: Pipeline with focus on Partnering, Investor science conference call from ESMO 2014, Roche investor conference call on the acquisition of InterMune, Roche Half-Year Results 2014 webcast and conference call, Roche Analyst Event on Diagnostics Division at AACC 2014, Sanford C. Bernstein's 30 Annual Strategic Decisions Conference, Bank of America Merrill Lynch 2014 Health Care Conference, Exane BNP Paribas 15th Healthcare Conference, Cowen and Company 34th Annual Health Care Conference, JP Morgan 32nd Annual Healthcare Conference, Full Year 2013 Presentation with appendix, Roche Employee Action and Charity Trust (REACT), The Millennium Development Goals - Our contribution, Global Reporting Initiative (GRI) Content Index 2010.